BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $14.00 Consensus Target Price from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given an average recommendation of “Buy” by the seven brokerages that are covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $14.00.

A number of brokerages have issued reports on BCRX. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. JMP Securities upped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a report on Tuesday, May 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, Director Nancy J. Hutson purchased 5,000 shares of the company’s stock in a transaction on Monday, May 20th. The stock was acquired at an average cost of $6.38 per share, for a total transaction of $31,900.00. Following the completion of the transaction, the director now directly owns 86,818 shares in the company, valued at $553,898.84. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, Director Nancy J. Hutson purchased 5,000 shares of the firm’s stock in a transaction on Monday, May 20th. The shares were bought at an average cost of $6.38 per share, for a total transaction of $31,900.00. Following the completion of the purchase, the director now directly owns 86,818 shares of the company’s stock, valued at $553,898.84. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Alan G. Levin acquired 7,861 shares of the company’s stock in a transaction dated Thursday, May 30th. The stock was purchased at an average cost of $6.36 per share, with a total value of $49,995.96. Following the completion of the purchase, the director now directly owns 44,951 shares of the company’s stock, valued at approximately $285,888.36. The disclosure for this purchase can be found here. Insiders have purchased 103,601 shares of company stock valued at $596,338 over the last 90 days. 4.80% of the stock is owned by insiders.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 15.4% in the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock valued at $106,405,000 after purchasing an additional 2,371,401 shares in the last quarter. Norges Bank acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth $13,278,000. Kynam Capital Management LP increased its position in shares of BioCryst Pharmaceuticals by 41.9% during the first quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock worth $33,160,000 after acquiring an additional 1,927,491 shares during the period. Avoro Capital Advisors LLC raised its stake in shares of BioCryst Pharmaceuticals by 13.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock valued at $78,170,000 after acquiring an additional 1,500,000 shares in the last quarter. Finally, abrdn plc purchased a new position in BioCryst Pharmaceuticals in the fourth quarter valued at $3,022,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Up 8.5 %

NASDAQ:BCRX opened at $7.04 on Friday. The company has a market cap of $1.45 billion, a P/E ratio of -6.58 and a beta of 1.88. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $7.95. The company’s 50-day moving average price is $6.19 and its 200-day moving average price is $5.66.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. The company had revenue of $92.80 million for the quarter, compared to analyst estimates of $85.62 million. During the same quarter in the prior year, the firm earned ($0.28) earnings per share. The company’s revenue for the quarter was up 34.9% on a year-over-year basis. On average, analysts expect that BioCryst Pharmaceuticals will post -0.66 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.